{"id":"NCT05715528","sponsor":"Gilead Sciences","briefTitle":"Study of Obeldesivir in Nonhospitalized Participants With COVID-19","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-02-08","primaryCompletion":"2023-11-28","completion":"2024-01-23","firstPosted":"2023-02-08","resultsPosted":"2024-12-24","lastUpdate":"2024-12-24"},"enrollment":2011,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Obeldesivir","otherNames":["GS-5245"]},{"type":"DRUG","name":"Obeldesivir Placebo","otherNames":[]}],"arms":[{"label":"Obeldesivir","type":"EXPERIMENTAL"},{"label":"Obeldesivir Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.","primaryOutcome":{"measure":"Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29","timeFrame":"First dose date up to Day 29","effectByArm":[{"arm":"Obeldesivir","deltaMin":5.9,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0681"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":113,"countries":["United States","Japan"]},"refs":{"pmids":["40675167"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-611-6549"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":979},"commonTop":[]}}